The U.S. Centers for Disease Control and Prevention (CDC) proposes to offer a contract opportunity to Rensselaer Polytechnic Institute to run a study on a potential link between vaccination and autism prevalence, according to data from a federal website.
A notice posted on Sep. 11 on the SAM.gov website indicated that the CDC’s Office of Acquisition Services intends to offer the fixed-price contract to Rensselaer Polytechnic, a private research university based in New York.
“The vendor has unique ability to link children to maternal cohorts using proprietary databases and de-identified data sets, enabling advanced statistical analyses within the project’s timeframe,” the posting read.
The CDC is expected to decide whether to conduct a competitive bidding process for the contract after evaluating all quotations and responses submitted within 15 days of the notice.
The proposal follows a Reuters report in March, which indicated that the agency is planning to conduct an extensive study to see whether there is a potential connection between vaccines and autism.
Leading vaccine makers: GSK (NYSE:GSK), Merck (MRK), Moderna (NASDAQ:MRNA), BioNTech (BNTX), Pfizer (NYSE:PFE), Novavax (NVAX), and Sanofi (NASDAQ:SNY).
Dear readers: We recognize that politics often intersect with the financial news of the day, so we invite you to click here to join the separate political discussion.